Curie.Bio
Joshua Mugford is an accomplished scientist with extensive experience in drug discovery and biology, currently serving as Drug Maker in Residence at Curie.Bio since October 2023. Prior to this role, Joshua held various positions at Zentalis Pharmaceuticals, including Director and Associate Director of Discovery Biology from February 2021 to October 2023. Previous roles at Bristol Myers Squibb and Celgene involved senior scientific responsibilities focused on epigenetics and oncology. Joshua’s career began with a post-doctoral fellowship at the University of North Carolina at Chapel Hill, followed by graduate studies at Harvard University, where a PhD in Biology - Developmental Genetics was earned. Educational background also includes a B.S. in Biological Sciences from Carnegie Mellon University. Research expertise spans epigenomic engineering, therapeutic development, and cross-functional collaboration in life sciences.
This person is not in any teams
Curie.Bio
2 followers
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.